PharmaVentures Podcast Series

Adrian Dawkes talks to PharmaVentures’ Founder and CEO, Dr Fintan Walton, about the importance of strategy and preparation in today’s deal making space. In the competitive, fast-paced environment of deal making within the life sciences industry, if you fail to prepare, then you must prepare to fail. Tune in to help assemble your strategy for success.

Join Adrian Dawkes, Managing Director at PharmaVentures, for this podcast episode exploring how the pharmaceutical manufacturing sector is evolving in response to shifting global pressures. Our experts, Ross Jenkins and Dr Gurdas Singh, unpack the critical changes shaping the industry.

In this podcast, PharmaVentures explores the recent changes in the landscape of Drug Pricing. This episode delves into the evolving differences between Europe and the US and how it has an impact on both. It also assesses the how Direct-to-Patient strategies, now being deployed by pharmaceutical companies in the US, can change the cost to the patient.

Adrian Dawkes talks to PharmaVentures Founder and CEO, Fintan Walton about how companies can navigate risk and even deploy new strategies in times of increased uncertainty.

Fintan Walton, founder and CEO of PharmaVentures chairs a round table discussion on this pressing issue.

Adrian Dawkes talks to PharmaVentures Founder and CEO Fintan Walton about his experience from over 30 years of dealmaking. In particular, why innovator biotechs and their investors are weaker when they underestimate the significance of both understanding and communicating their commercial strategy for their lead assets in negotiations

Listen as Adrian Dawkes talks to Kurt Herpel, CEO and Klaus Kratochwill, CSO of Delta 4, an Austrian /Swiss based AI tech company. Hear how their AI journey began more than 20 years ago and how the company developed into a key player in AI drug discovery. Hear how their clients are already benefiting from AI.

Listen as Soren Demin draws on his 20 years of M&A experience to provide insight into the current Pharma/Biotech M&A landscape.

Listen as Andreas Katsiamides talks with Adrian Dawkes about the future of diagnostics and the impact on deals.

Listen as Colin McCall, Partner – Life Sciences and Deep Tech at Taylor Wessing, and Oliver Pumfrey, Managing Director at FTI Consulting, talk with Adrian Dawkes about law and tax during the licensing and M&A deal making process.

Ralph Hughes takes the listener through the process of commercial due diligence and evaluation, including the key stakeholders and insights needed to understand whether the asset is going to achieve strong performance in the marketplace.

Listen as Andrew Guise gives key insight into the deal making landscape – asset value, accessing the market, positioning and the actual deal process in the current economic climate – from the unique position standing astride both the financial world and the technical world translating science into value.